

PRODUCT MONOGRAPH

Pr Vancomycin Hydrochloride Capsules, USP

vancomycin (as vancomycin hydrochloride)
125 mg and 250 mg

USP

Antibiotic

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite100
Toronto, ON, M9W 0C8

Date of Revision:
November 22, 2017

Submission Control No: 196466

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION	3
SUMMARY PRODUCT INFORMATION.....	3
INDICATIONS AND CLINICAL USE	3
CONTRAINDICATIONS.....	4
WARNINGS AND PRECAUTIONS	4
ADVERSE REACTIONS	6
DRUG INTERACTIONS	7
DOSAGE AND ADMINISTRATION	7
OVERDOSAGE.....	8
ACTION AND CLINICAL PHARMACOLOGY	8
STORAGE AND STABILITY	8
DOSAGE FORMS, COMPOSITION AND PACKAGING.....	9
PART II: SCIENTIFIC INFORMATION	10
PHARMACEUTICAL INFORMATION.....	10
DETAILED PHARMACOLOGY	11
MICROBIOLOGY	11
TOXICOLOGY.....	14
REFERENCES.....	16
PATIENT MEDICATION INFORMATION	19

Pr Vancomycin Hydrochloride Capsules, USP

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Oral	Capsule / vancomycin 125 mg and 250 mg (as vancomycin hydrochloride)	<i>For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</i>

INDICATIONS AND CLINICAL USE

Vancomycin Hydrochloride Capsules, USP are indicated for treatment of infections caused by susceptible strains of the designated microorganisms in the following diseases and specific conditions:

staphylococcal enterocolitis, and
antibiotic-associated pseudomembranous colitis produced by *Clostridium difficile*.

Parenteral administration of vancomycin hydrochloride is not effective for the indicated conditions; therefore vancomycin hydrochloride must be given orally.

Vancomycin Hydrochloride Capsules, USP is not effective by the oral route for the treatment of other types of infection.

Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety and a brief discussion can be found in the Warnings and Precautions section.

Pediatrics: Evidence from clinical studies and experience suggests that use in premature neonates and young infants is associated with differences in safety and a brief discussion can be found in the Warnings and Precautions section.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride and other antibacterial drugs, vancomycin hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Because some strains

are resistant to vancomycin, when applicable, appropriate specimens should be obtained before antibacterial treatment, to determine the causative organism(s) and susceptibility to vancomycin.

CONTRAINDICATIONS

Vancomycin Hydrochloride Capsules, USP is contraindicated for patients who are hypersensitive to vancomycin hydrochloride or to any ingredient in the formulation or component of the container. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section.

WARNINGS AND PRECAUTIONS

General

Vancomycin hydrochloride is poorly absorbed orally. Toxic serum levels are therefore not expected from oral dosage. Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of vancomycin for active *C. difficile*-induced pseudomembranous colitis; therefore, monitoring of serum concentrations may be appropriate in these patients.

When given intravenously, toxic serum levels can occur. During parenteral therapy, the risk of toxicity appears appreciably increased by high blood concentrations or prolonged treatment.

Ear/Nose/Throat

Ototoxicity has occurred when serum levels exceeded 80 mcg/mL. Deafness may be preceded by tinnitus. Deafness may be transient or permanent. The elderly are more susceptible to auditory damage. Deafness may be progressive despite cessation of treatment.

Vancomycin hydrochloride should be avoided (if possible) in patients with previous hearing loss. If it is used in such patients, the dose of vancomycin hydrochloride should be regulated by periodic determination of drug levels in the blood. Patients with renal insufficiency and individuals over the age of 60 should be given serial tests of auditory function and of vancomycin blood levels.

Gastrointestinal

Some patients with inflammatory disorders of the intestinal mucosa may have significant systemic absorption of oral vancomycin and, therefore, may be at risk for the development of adverse reactions associated with the parenteral administration of vancomycin. The risk is greater if renal impairment is present.

Hematologic

Neutropenia can occur starting one week or more after onset of therapy with vancomycin hydrochloride or after a total dose of more than 25 g. Neutropenia appears to be promptly reversible when treatment is discontinued.

Renal

Because of its ototoxicity and nephrotoxicity, vancomycin hydrochloride should be used with care in patients with renal insufficiency. Vancomycin is excreted fairly rapidly by the kidney and blood levels increase markedly with decreased renal clearance. There is an increased risk of renal failure in patients receiving large doses of vancomycin hydrochloride.

In patients with underlying renal dysfunction or those receiving concomitant therapy with an aminoglycoside there is a risk of developing interstitial nephritis. When these patients are being treated with vancomycin hydrochloride, serial monitoring of renal function should be performed.

Susceptibility/Resistance

Development of Drug Resistant Bacteria

The prolonged use of vancomycin hydrochloride may result in overgrowth of non-susceptible organisms. If new infections due to bacteria or fungi appear during therapy with this product, appropriate measures should be taken, including withdrawal of vancomycin hydrochloride .

In vitro resistance to vancomycin has been reported among some enterococcal and staphylococcal isolates.

Vancomycin is not effective *in vitro* against gram-negative bacilli, mycobacteria, or fungi.

Prescribing vancomycin hydrochloride in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.

Special Populations

Pregnant Women:

Vancomycin hydrochloride should be given to pregnant women only if clearly needed. In a controlled study, Vancomycin hydrochloride was administered to 10 pregnant women for serious staphylococcal infections complicating intravenous drug abuse to evaluate potential ototoxic and nephrotoxic effects on the infant. Vancomycin hydrochloride levels of 13.2 and 16.6 mcg/mL were measured in cord blood in two patients. No sensorineural hearing loss or nephrotoxicity attributable to vancomycin hydrochloride was noted. One infant whose mother received vancomycin hydrochloride in the third trimester experienced conductive hearing loss that was not attributed to the administration of vancomycin hydrochloride. Because the number of patients treated in this study was limited and vancomycin hydrochloride was administered only in the second and third trimesters, it is not known whether vancomycin hydrochloride causes fetal harm.

Nursing Women:

Vancomycin hydrochloride is excreted in human milk. Caution should be exercised if vancomycin hydrochloride is administered to a nursing woman. Because of the potential for adverse events, a decision should be made whether to discontinue nursing or discontinue administration of the drug, taking into account the importance of the drug to the mother.

Pediatrics (*premature neonates and young infants*):

It may be appropriate to confirm desired vancomycin serum concentrations. Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing in children.

Geriatrics:

The natural decrease of glomerular filtration with increasing age may lead to elevated vancomycin serum concentrations if dosage is not adjusted. Vancomycin dosage schedules should be adjusted in elderly patients. It should be noted that the total systemic and renal clearances of vancomycin are reduced in the elderly. The elderly are more susceptible to auditory damage.

Monitoring and Laboratory Tests:

All patients receiving the drug should have periodic hematologic studies, urinalyses, and liver and renal function tests.

ADVERSE REACTIONS**Adverse Drug Reaction Overview****Nephrotoxicity:**

Rarely, renal failure, principally manifested by increased serum creatinine or blood urea nitrogen (BUN) concentrations, especially in patients given large doses of vancomycin hydrochloride has been reported. Rare cases of interstitial nephritis have been reported. Most of these have occurred in patients who were given aminoglycosides concomitantly or who had pre-existing kidney dysfunction. When vancomycin hydrochloride was discontinued, azotemia resolved in most patients.

Ototoxicity:

A few dozen cases of hearing loss associated with vancomycin hydrochloride have been reported. Most of these patients had kidney dysfunction, pre-existing hearing loss, or concomitant treatment with an ototoxic drug. Vertigo, dizziness, and tinnitus have been reported rarely.

Hematopoietic:

Reversible neutropenia, usually starting one week or more after onset of therapy with vancomycin hydrochloride or after a total dose of more than 25 g, has been reported in several dozen patients. Neutropenia appears to be promptly reversible when vancomycin hydrochloride is discontinued. Thrombocytopenia has rarely been reported. Although a causal relationship has not been established, reversible agranulocytosis (granulocyte count less than $500/\text{mm}^3$) has been reported rarely. Eosinophilia has been associated with the administration of vancomycin hydrochloride.

Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome (DRESS)**Toxic Epidermal Necrolysis (TEN)**

Miscellaneous:

Anaphylaxis, drug fever, nausea, chills, hypotension, wheezing, dyspnea, urticaria, pruritus, flushing of the upper body (“red neck”), pain and muscle spasm of the chest and back, rashes, including exfoliative dermatitis, Stevens-Johnson syndrome, linear IgA bullous dermatosis and rare cases of vasculitis have been associated with the administration of vancomycin hydrochloride.

DRUG INTERACTIONS**Overview****Drug-Drug Interactions**

Concurrent and sequential use of other neurotoxic and/or nephrotoxic agents, particularly ethacrynic acid, neuromuscular blocking agents, aminoglycoside antibiotics, polymixin B, colistin, viomycin, and cisplatin, requires careful monitoring.

Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing in children.

Drug-Food Interactions

Interactions studies between vancomycin hydrochloride and food have not been conducted.

Drug-Herb Interactions

Interactions studies between vancomycin hydrochloride and herbs have not been conducted.

Drug-Laboratory Test Interactions

Interactions studies between vancomycin hydrochloride and laboratory tests have not been conducted.

DOSAGE AND ADMINISTRATION**Dosing Considerations**

If parenteral and oral vancomycin are administered concomitantly an additive effect can occur. This should be taken into consideration when calculating the total dose. In this situation serum levels of the antibiotic should be monitored.

Vancomycin Hydrochloride Capsules, USP capsules are formulated in a matrix gel that prevents administration by a nasogastric tube; if this route of administration is being considered; the intravenous dosage form should be used.

Recommended Dose and Dosage Adjustment**Adults:**

The usual daily dosage for antibiotic-associated pseudomembranous colitis produced by *C. difficile*

and staphylococcal enterocolitis is 125 to 500 mg administered orally every 6 to 8 hours for 7 to 10 days.

Pediatrics:

The usual daily dosage is approximately 40 mg/kg in 3 or 4 divided doses for 7 to 10 days administered orally. The total daily dosage should not exceed 2 g.

Missed Dose

If a dose of this medication has been missed, it should be taken as soon as possible. However, if it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double doses.

OVERDOSAGE

Activated charcoal may be administered to aid in the removal of unabsorbed drug. General supportive measures are recommended.

Other than general supportive treatment, no specific antidote is known. Dialysis does not remove significant amounts of vancomycin. Hemofiltration and hemoperfusion with polysulfone resin have been reported to result in increased vancomycin clearance.

In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in the patient.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

In vitro studies indicate that the bactericidal action of vancomycin hydrochloride against many gram-positive bacteria results from the inhibition of cell-wall synthesis. There is also evidence that vancomycin alters the permeability of the cell membrane and selectively inhibits RNA synthesis.

STORAGE AND STABILITY

Temperature:

- Store vancomycin capsules at room temperature (15° to 25°C).

Moisture:

- Protect from moisture.

Others:

- Keep out of sight and reach of children.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Vancomycin Hydrochloride Capsules, USP contain vancomycin hydrochloride, (expressed in terms of free base) and polyethylene glycol 6000. The capsules also contain FD&C Blue No.2, gelatin, iron oxide, and titanium dioxide.

Vancomycin Hydrochloride Capsules, USP equivalent to 125 mg (0.08 mmol) vancomycin and 250 mg (0.17 mmol) vancomycin are available in (unit-dose) packages of 20 capsules.

Vancomycin Hydrochloride Capsules, USP 125 mg: A size 2, grey/light grey hard gelatin capsule with a white to slightly red or slightly brown solid mass.

Vancomycin Hydrochloride Capsules, USP 250 mg: A size 0, green/turquoise hard gelatin capsule with a white to slightly red or slightly brown solid mass.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: Vancomycin hydrochloride


Chemical Name:

(Sa)-(3S,6R,7R,22R,23S,26S,36R,38aR)-44-[[2-0-(3-Amino-2,3,6-trideoxy-3-C-methyl- α -L-lyxo-hexopyranosyl)- β -D-glucopyranosyl]oxy]-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-[(2R)-4-methyl-2-(methylamino)valeramido]-2,5,24,38,39-pentaoxo-22H-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1H,16H-[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]-benzoxadiazacyclo-tetracosine-26, carboxylic acid, monohydrochloride

Molecular formula: $C_{66}H_{75}Cl_2N_9O_{24} \cdot HCl$

Molecular mass: 1485.68 g/mol

Structural formula:



Physicochemical properties: Vancomycin hydrochloride is a chromatographically purified tricyclic glycopeptide antibiotic derived from *Amycolatopsis orientalis* (formerly *Nocardia orientalis*). It is an off-white free flowing powder, having essentially no odour. It is soluble in water and insoluble in organic solvents.

DETAILED PHARMACOLOGY

Human Pharmacology

Adults:

Renal Insufficiency:

Infusions of 1 g vancomycin in 250 mL D5W were given over 30 minutes to 29 anephric patients. After 18 days with intermittent dialysis at three-day intervals, the serum concentration was still 3.5 mcg/mL. The elimination half-life was about 7.5 days.

Oral Administration:

Vancomycin hydrochloride is poorly absorbed after oral administration, only trace amounts being found in blood or urine. Following 125 mg orally 4 times daily, the mean concentration of vancomycin in stools was approximately 350 mcg/g. Following up to ten daily oral doses of 2 g, a mean level of 3100 mcg/g with a range of 905 - 8760 mcg/g was detected in feces of patients with pseudomembranous colitis.

Tissue Penetration and Distribution:

Central Nervous System:

Vancomycin does not readily diffuse across normal meninges into the spinal fluid; but, when the meninges are inflamed, penetration into the spinal fluid occurs.

Other Tissues and Fluids:

Vancomycin concentration in human pericardial, pleural, bile, ascetic and synovial fluids reaches approximately one third of the equivalent serum level after single intravenous doses. A level of 7.6 mcg/mL was achieved in the brain cyst of one infant following intravenous infusion of 40 mg/kg daily for 4 days.

MICROBIOLOGY

Cross-resistance has not been demonstrated between vancomycin hydrochloride and other classes of antibiotics. Laboratory-induced resistance has been reported to occur in a slow stepwise fashion. Its activity is not significantly altered by changes in pH or by the presence of serum.

Vancomycin is active against most strains of the following organisms *in vitro* and in clinical infections as described in the section **INDICATIONS AND CLINICAL USE**:

Staphylococcus aureus (including heterogeneous methicillin-resistant strains)

Clostridium difficile

Vancomycin is active against most strains of the following organisms *in vitro*. However, the safety and effectiveness of vancomycin in treating clinical infections due to these organisms have not been established in adequate and well-controlled trials.

Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains)
Streptococcus pneumoniae (including multiple-resistant strains)
Streptococcus pyogenes (group A beta-hemolytic)
Streptococcus agalactiae (group B beta-hemolytic)
Streptococcus bovis
Alpha-hemolytic *streptococci* (*viridans* groups)
Enterococci (e.g. *E. faecalis*)
Bacillus sp.
Listeria monocytogenes
Lactobacillus sp.
Neisseria sp.
Diphtheroids
Actinomyces sp.

Note: Many strains of *streptococci*, *staphylococci*, *C. difficile*, and other gram-positive bacteria are susceptible *in vitro* to concentrations of 0.5 to 5 mcg/mL. *Staphylococci* are generally susceptible to less than 5 mcg/mL of vancomycin hydrochloride, but a small proportion of *S. aureus* strains require 10 to 20 mcg/mL for inhibition.

In vitro resistance to vancomycin has been reported among some enterococcal and staphylococcal isolates.

Vancomycin is not effective *in vitro* against gram-negative bacilli, mycobacteria, or fungi.

Table 1: In Vitro Activity of Vancomycin

Organism	No. of Strains	MIC* (mcg/mL) Range	Median
<i>Staphylococcus aureus</i>	55	1.0 – 2.0	1.0
	101	0.78 – 12.5	3.1
	35	0.25 – 1.0	1.0
<i>Staphylococcus aureus</i> (methicillin-resistant)	22	0.5 – 4.0	0.5
	38	0.3 – 12.0	1.5
	12	0.2 – 3.12	0.4
<i>Streptococcus epidermidis</i>	177	1.56 – 6.25	3.1
	35	0.4 – 3.1	1.6
	27	0.2 – 6.25	3.12
<i>Streptococcus pneumoniae</i>	70	0.125 – 0.5	0.25
<i>Streptococcus pyogenes</i>	12	0.8 – 3.1	1.6
<i>Streptococcus viridans</i>	82	0.39 – 1.56	0.78
<i>Streptococcus</i> group D <i>Enterococci</i>	382	0.8 - > 100.0	3.1
<i>Clostridium perfringens</i>	43	0.4 – 1.6	0.8
<i>Clostridium ramosum</i>	49	3.1 – 12.5	6.2
<i>Clostridium difficile</i>	14	< 1.0	< 1.0
	78	1.0 – 4.0	

*Minimum Inhibitory Concentration (MIC)

Methods of Susceptibility Testing:

When the standardized method of disc susceptibility testing is used, a 30 mcg disc of vancomycin should produce a zone of *more than* 11 mm when in contact with “susceptible” organisms. A zone size of 10 – 11 mm indicates intermediate susceptibility, while a zone size of 9 mm or less indicates resistance.

With the WHO-ICS agar dilution and broth dilution methods, a MIC of ≤ 5 mcg/mL indicates susceptibility to vancomycin.

Assay Methods:

Vancomycin serum and tissue levels may be determined by Bennett’s agar-well diffusion method. This test can quantitatively measure vancomycin concentrations from 0.5 to 0.8 mcg/mL. Two disc-diffusion assay methods are available for vancomycin. Both use *Bacillus subtilis* as the test organism. The first method, which uses antibiotic medium No. 5, is capable of measuring

vancomycin levels from approximately 5 to 40 mcg/mL. The second uses minimal salt agar and is capable of detecting vancomycin concentrations from about 0.8 to 25 mcg/mL.

A modification of this assay permits reliable bioassay for vancomycin (in concentrations of 0.78 to 50.0 mcg/mL) in the presence of rifampin or aminoglycosides. Two commercially prepared assay methods are now available and include a radioimmunoassay and an automated fluorescence polarization immunoassay.

TOXICOLOGY

Acute Toxicity

Vancomycin was administered to mice, rats and dogs by various routes.

Table 2: LD₅₀ ± SE (mg/kg) following vancomycin administration

Route of Administration	Rat	Mouse	Dog
Intravenous	319 ± 14	489 ± 41	292 ± 29
Intraperitoneal	2 218 ± 240	1 734 ± 227	
Subcutaneous		> 5 000	
Oral		> 5 000	

Rats died quickly from CNS-mediated effects, while dogs died, generally from kidney failure, several days after the intravenous administration.

Vancomycin, when administered intravenously in a 5 percent solution to dogs at a rate of 0.6 mL/minute, caused a slight dose-related drop in blood pressure. When the same dogs were given the same doses at a rate of 15 mL/minute, blood pressure dropped dramatically, as much as 40 percent. Whether the response is due to a direct effect on histamine receptors or to release of histamine, possibly from mast cells, is not known.

Subchronic Toxicity

Dogs were given daily intravenous doses of vancomycin at 12.5 mg and 50 mg/kg for 21 - 311 days. Renal damage was seen in 4/22 dogs receiving 50 mg/kg/day.

Monkeys tolerated intravenous doses of 25 and 50 mg/kg/day for 16 - 187 days, with irritation at the injection site as the only toxic effect.

Cats received intravenous doses of 25 and 50 mg/kg/day for three months with no systemic toxicity.

Anaphylaxis could not be induced in 9 guinea pigs that received 100 mg vancomycin subcutaneously when challenged by a 25 mg intravenous dose, 25 days later.

Intraperitoneal doses of 150 mg vancomycin or 60 mg tobramycin given subcutaneously to rats, resulted in no nephrotoxicity; however, when administered together, significant renal toxicity occurred.

Vancomycin 1 000 mg/kg administered subcutaneously concurrently with ethacrynic acid 40 mg/kg intravenously, did not produce ototoxicity in a guinea pig model.

Neuromuscular blocking has not been demonstrated in vancomycin-treated rabbits.

REFERENCES

1. Bartlett JG. Antibiotic-associated pseudomembranous colitis. *Hospital Practice (Off Ed)*. 1981 Dec; 16 (12):85-8, 93-5. PubMed PMID: 6796495.
2. Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. *Rev-Infect Dis*. 1984 Mar-Apr; 6 Suppl 1:S235-S241. PubMed PMID: 6718937.
3. Burdon DW. Treatment of pseudomembranous colitis and antibiotic-associated diarrhoea. *J Antimicrob Chemother*. 1984 Dec; 14Suppl. D:103-9. Review. PubMed PMID: 6394575.
4. Cooper GL, Given DB. Vancomycin – a comprehensive review of 30 years of clinical experience. Park Row Publishers Inc. Jan 1986.
5. Cunha BA, Ristuccia AM. Clinical usefulness of vancomycin. *Clin. Pharm*. 1983 Sep-Oct; 2 (5): 417-424. Review. PubMed PMID: 6354567.
6. Dudley MD, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for *Clostridium difficile*-induced diarrhea. A randomized double-blind trial. *Arch Intern Med*. 1986 Jun; 146 (6):1101-4. PubMed PMID: 3521518.
7. Fekety R. Recent advances in management of bacterial diarrhea. *Rev Infect Dis*. 1983 Mar-Apr; 5(2): 246-57. PubMed PMID: 6405474.
8. Fekety R, Silva J, Buggy B, Deery HG. Treatment of antibiotic-associated colitis with vancomycin. *J Antimicrob Chemother*. 1984 Dec; 14 Suppl D:97-102. PubMed PMID: 6520070.
9. Finegold SM, Gaylor DW. Enterocolitis due to phage type 54 staphylococci resistant to kanamycin, neomycin, paromomycin and chloramphenicol. *N Engl J Med*. 1960 Dec 1; 263:1110-6. PubMed PMID: 13699584.
10. Geraci JE, Heilman FR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. *Proc Staff Meet Mayo Clinic*. 1958 Apr 2; 33 (7):172-81. PubMed PMID: 13542649.
11. Geraci JE, Heilman FR, Nichols DR, Ross GT, Wellmann WE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. *Proc Staff Meet Mayo Clinic*. 1956 Oct 17; 31 (21):564-82. PubMed PMID: 13370625.
12. Geraci JE, Hermans PE. Vancomycin. *Mayo Clinic Proc*. 1983 Feb; 58 (2):88-91. PubMed PMID: 6823162.
13. Griffith RS. Vancomycin use – an historical review. *J Antimicrob Chemother*. 1984

- Dec;14 Suppl D:1-5. PubMed PMID: 6394574.
14. Griffith RS, Peck FB Jr. Vancomycin, a new antibiotic. III. Preliminary clinical and laboratory studies. *Antibiot Annu.* 1955-1956; 3: 619-22. PubMed PMID: 13355338.
 15. Kaplan EL. Vancomycin in infants and children: A review of pharmacology and indications for therapy and prophylaxis. *J Antimicrob Chemother.* 1984 Dec; 14 Suppl D: 59-66. Review. PubMed PMID: 6394578.
 16. Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: Microbiologic and clinical observations as guides to therapy. *Ann Intern Med.* 1983 Apr; 98 (4):447-455. PubMed PMID: 6838067.
 17. Keighley MR. Pseudomembranous colitis. *Schweiz Rundsch Med Prax.* 1982 Jan 19; 71 (3): 98-106. PubMed PMID: 7038661.
 18. Khan MY, Hall WH. Staphylococcal enterocolitis – treatment with oral vancomycin. *Ann Intern Med.* 1966 Jul; 65(1): 1-8. PubMed PMID: 5936663.
 19. Kirby WMM. Vancomycin therapy of severe staphylococcal infections. *J Antimicrob Chemother.* 1984 Dec; 14 (Suppl. D):73-8. PubMed PMID: 6394579.
 20. Marrie TJ, Furlong M, Faulkner RS, Sidorov J, Haldane EV, Kerr EA. Clostridium difficile: Epidemiology and clinical features. *Can J Surg.* 1982 Jul; 25(4):438-442. PubMed PMID: 7093841.
 21. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. *Antimicrob Agents Chemother.* 1984 Apr; 25(4):433-7. PubMed PMID: 6732213; PubMed Central PMCID: PMC185546.
 22. McCormick MH, McGuire JM, Pittenger GE, Pittenger RC, Stark WM. Vancomycin, a new antibiotic. I. Chemical and biologic properties. *Antibiotics Annu.* 1955-1956; 3: 606-11. PubMed PMID: 1355336.
 23. McGuire JM, Wolfe RN, Ziegler DW. Vancomycin a new antibiotic. II. *In vitro* antibacterial studies. *Antibiot Annu.* 1955-1956;3: 612-8 PubMed PMID: 13355337.
 24. McHenry MC, Gavan TL. Vancomycin. *Pediat Clin North Am.* 1983 Feb; 30 (1): 31-37. PubMed PMID: 6338468.
 25. Moellering RC Jr. Pharmacokinetics of vancomycin. *J Antimicrob Chemother.* 1984 Dec; 14 Suppl D: 43-52. Review. PubMed PMID: 6394577.
 26. Pfaller MA, Krogstad JD, Granich GG, Murray PR. Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay. *J Clin*

- Microbiol. 1984 Sep; 20 (3):311-6. PubMed PMID: 6386852; PubMed Central PMCID: PMC271319
27. Shuttleworth R, Taylor M, Jones DM. Antimicrobial susceptibilities of *Clostridium difficile*. *J. Clin Pathol.* 1980 Oct; 33 (10):1002-5. PubMed PMID: 7430354; PubMed Central PMCID: PMC1146303.
 28. Thomas DF, Fernie DS, Malone M, Bayston R, Spitz L. Association between *Clostridium difficile* and enterocolitis in Hirschsprung's Disease. *Lancet.* 1982 Jan 9; 1 (8263):78-9. PubMed PMID: 6119496.
 29. Wallace JF, Smith RH, Petersdorf RG. Oral administration of vancomycin in the treatment of staphylococcal enterocolitis. *N Engl J Med.* 1965 May 13; 272:1014-5. PubMed PMID: 14279249.
 30. Watanakunakorn C. Mode of action and in vitro activity of vancomycin. *J Antimicrob Chemother.* 1984 Dec; 14 Suppl D: 7-18. Review. PubMed PMID: 6440886.
 31. Welch DF, Marks MI. Is *Clostridium difficile* pathogenic in infants? *Pediatr.* 1982 Mar; 100(3): 393-5. PubMed PMID: 7062169.
 32. Wise RI, et al. The vancomycin symposium: summary and comments. *Rev Infect Dis.* 1981 Nov-Dec; 3:S293-300.
 33. Woodley DW, Hall WH. The treatment of severe staphylococcal infections with vancomycin. *Ann Intern Med.* 1961 Aug; 55:235-49. PubMed PMID: 13786545.
 34. VANCOCIN® (Vancomycin Hydrochloride Capsules), Innovator Product Monograph, Merus Labs Inc., Control No.203124, October 27, 2017.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

^{Pr}Vancomycin Hydrochloride Capsules, USP (vancomycin hydrochloride)

Read this carefully before you start taking **Vancomycin Hydrochloride Capsules, USP** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Vancomycin Hydrochloride Capsules, USP**.

What is Vancomycin Hydrochloride Capsules, USP used for?

Vancomycin Hydrochloride Capsules, USP is an antibiotic. It is used to treat bacterial infections of the intestine such as pseudomembranous colitis or colitis. Colitis refers to swelling or inflammation of the large intestine (colon) that may occur due to an overgrowth of *Clostridium difficile* (*C difficile*) bacteria. This infection is a common cause of diarrhea after antibiotic use.

Antibacterial drugs like Vancomycin Hydrochloride Capsules, USP treat only bacterial infections. They do not treat viral infections such as the common cold. Although you may feel better early in treatment, Vancomycin Hydrochloride Capsules, USP should be used exactly as directed. Misuse or overuse of Vancomycin Hydrochloride Capsules, USP could lead to the growth of bacteria that will not be killed by Vancomycin Hydrochloride Capsules, USP (resistance). This means that Vancomycin Hydrochloride Capsules, USP may not work for you in the future. Do not share your medicine.

How does Vancomycin Hydrochloride Capsules, USP work?

Vancomycin is in a class of medications called glycopeptide antibiotics. It works by killing certain bacteria in the intestines.

What are the ingredients in Vancomycin Hydrochloride Capsules, USP?

Medicinal ingredients: Vancomycin hydrochloride.

Non-medicinal ingredients: FD&C Blue No.2, gelatin, iron oxide, polyethylene glycol 6000, and titanium dioxide.

Vancomycin Hydrochloride Capsules, USP comes in the following dosage forms:

Vancomycin Hydrochloride Capsules, USP comes as capsules to take by mouth.

Vancomycin Hydrochloride Capsules, USP is available in two strengths containing 125mg or 250mg of vancomycin (as vancomycin hydrochloride).

Do not use Vancomycin Hydrochloride Capsules, USP if you are allergic to:

- vancomycin hydrochloride
- any ingredient in the formulation or component of the container. (Please see “What are the ingredients in Vancomycin Hydrochloride Capsules, USP ?” section above).

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Vancomycin Hydrochloride Capsules, USP. Talk about any health conditions or problems you may have, including if you:

- You have hearing problems
- You have had previous hearing loss
- You have kidney problems
- You have or have ever had:
 - inflammatory bowel disease (swelling of the intestine that can cause painful cramps or diarrhea)
 - Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever)

- ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum)
Vancomycin Hydrochloride Capsules, USP works mainly in the intestines and does not get in the blood. If you have problems in the intestines some medicine may get into blood and you may have some side effects
- You are pregnant or planning to become pregnant
- You are nursing or planning to nurse (Vancomycin is excreted in breast milk)

Other warnings you should know about:

While you are using Vancomycin Hydrochloride Capsules, USP

- Your healthcare professional may require that you do regular liver, kidney, blood or urine tests.
- If you are 65 or older, you could have more side effects. The risk of hearing or kidneys problems may be greater in older adults. See “Serious side effects and what to do about them” table for signs of hearing or kidneys problems.
- **Driving and using machines:** Ringing in your ears and dizziness have been reported and this may affect your ability to drive and use machines.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Vancomycin Hydrochloride Capsules, USP:

- Ethacrynic acid, a diuretic (“water pills”)
- Medications that affect your kidney or your nervous systems
- Medications given during surgery to relax the muscles (neuromuscular blocking agents)
- Other antibiotics such as:
 - Aminoglycoside antibiotics such as amikacin, gentamicin, kanamycin, paromomycin, tobramycin etc.
 - Polymixin B
 - Colistin
 - Viomycin (not marketed in Canada)
- Cisplatin, a medicine used to treat cancer

Always keep a list of your medicines and show it to your healthcare professional when you get a new medicine. It is important that your healthcare professional reviews all medications and supplements you are taking before prescribing Vancomycin Hydrochloride Capsules, USP.

How to take Vancomycin Hydrochloride Capsules, USP:

Take Vancomycin Hydrochloride Capsules by mouth. Vancomycin Hydrochloride capsules work mainly in the intestines.

Usual dose of Vancomycin Hydrochloride Capsules, USP:

- **Adults:** 125mg to 500mg 3 to 4 times a day for 7 to 10 days.
- **Children who can swallow:** The dose required will depend on the child weigh: 40mg/kg body weight daily in 3 or 4 doses for 7 to 10 days. The maximum daily dose is 2g.

Your healthcare professional will work out the right dose of Vancomycin Hydrochloride Capsules, USP for you or your child and how often it must be given each day. Ask your healthcare professional if you have any questions about Vancomycin Hydrochloride Capsules, USP dosing instructions.

Overdose:

If you think you have taken too much Vancomycin Hydrochloride Capsules, USP, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose of Vancomycin Hydrochloride Capsules, USP, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and continue with your next scheduled dose. Do not take two doses at the same time.

What are possible side effects from using Vancomycin Hydrochloride Capsules, USP?

These are not all the possible side effects you may feel when taking Vancomycin Hydrochloride Capsules, USP. If you experience any side effects not listed here, contact your healthcare professional.

Vancomycin Hydrochloride Capsules, USP may cause the following side effects:

- Drug fever
- Nausea
- Chills
- Itching, hives, skin rash
- Hypotension (low blood pressure): dizziness, fainting, light headedness

Tell your doctor or your healthcare professional if you experience any of the side effects listed above. Some side effects such as skin rash may be a sign of a more serious reaction.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
COMMON			
Allergic reactions: <ul style="list-style-type: none"> • severe rash, hives, itching • swelling of face, lips, mouth, throat or tongue • wheezing • tightness in the chest or throat • difficulty breathing or talking 			✓
Redness of the skin above your waist (“red neck”)			✓
RARE			

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<p>Blood problems such as:</p> <ul style="list-style-type: none"> • Loss of blood cells that help the blood clot (platelets): <ul style="list-style-type: none"> ○ unusual bleeding or bruising, ○ Nosebleeds ○ Pinpoint red spots on the skin • Low white blood cells (neutropenia): <ul style="list-style-type: none"> ○ more likely to develop infections, sore throat, fever, chills, and other signs of infection. • Increased numbers of certain white blood cells (eosinophilia): <ul style="list-style-type: none"> ○ rash, weight loss, wheezing, abdominal pain. 			✓
<p>Kidney problems:</p> <ul style="list-style-type: none"> • Swelling in the arms or legs, • fatigue • loss of appetite • nausea and vomiting • thirst • unable to pass urine • change in the amount of urine you pass 			✓
<p>Hearing problems:</p> <ul style="list-style-type: none"> • dizziness, problems with balance • vertigo (spinning sensation) • ringing in the ears (is a potential warning sign of hearing loss) • change in hearing • temporary or permanent hearing loss 			✓
Pain and muscle tightness of the chest and back			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<p>Serious life-threatening skin reactions (Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS)):</p> <ul style="list-style-type: none"> • unexplained widespread skin pain • flu-like symptoms (fever, sore mouth and throat, cough, burning eyes etc.) • followed by a painful red or purplish rash that spreads and blisters on mouth, nose, eyes and genitals • shedding of your skin within days after blisters form • swelling of the face or swollen glands in the neck, armpits or groin • yellowing of your skin or eye • dark urine, light-colored bowel movements; • severe nausea or vomiting; stomach pain 			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

<p>Reporting Side Effects</p> <p>You can report any suspected side effects associated with the use of health products to Health Canada by:</p> <ul style="list-style-type: none"> • Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or • Calling toll-free at 1-866-234-2345. <p><i>NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.</i></p>
--

Storage:

Store Vancomycin Hydrochloride Capsules at room temperature, 15° to 25°C. Protect from moisture. Do not use beyond the expiration date.
Keep out of reach and sight of children.

If you want more information about Vancomycin Hydrochloride Capsules, USP:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://health-products.canada.ca/dpd->

[bdpp/index-eng.jsp](#)); the manufacturer's website www.meruslabs.com, or by calling **Fresenius Kabi Canada Ltd.**, at 1-877-821-7724.

This leaflet was prepared by:
Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON, M9W 0C8

Last Revised: November 22, 2017